Colleen Schmitt, MD
Gastroenterology · Ooltewah, TNNPI 1528023512
Payments from drug & device makers
Across 322 payments — averaging $1031.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$209K
- Eli Lilly$58K
- Braintree Laboratories, Inc.$34K
- Regeneron$13K
- Adare Pharmaceuticals, Inc.$8K
- Olympus Corporation$3K
- plus $6K from 26 others
Across 4 payments — averaging $751.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3K
What the payments were for
- Consulting fees$3,99843%
- Speaking & faculty fees$1,56917%
- Food & beverage$3,70440%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 98 | $208,848 |
| Eli Lilly | 9 | $58,398 |
| Braintree Laboratories, Inc. | 13 | $34,231 |
| Regeneron | 3 | $13,070 |
| Adare Pharmaceuticals, Inc. | 1 | $8,400 |
| Olympus Corporation | 3 | $2,768 |
| Ferring Pharmaceuticals Inc. | 9 | $1,803 |
| AbbVie | 81 | $1,696 |
| Olympus Medical Systems Corporation | 1 | $1,230 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $322 |
| Pfizer | 19 | $240 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $161 |
| UCB, Inc. | 8 | $141 |
| Regeneron Healthcare Solutions, Inc. | 7 | $127 |
| Johnson & Johnson | 6 | $94 |
| Daiichi Sankyo Inc. | 6 | $94 |
| E.r. Squibb & Sons, L.L.C. | 1 | $90 |
| Janssen Scientific Affairs, LLC | 1 | $70 |
| Phathom Pharmaceuticals, Inc. | 3 | $49 |
| Bristol Myers Squibb | 2 | $43 |
| Ardelyx, Inc. | 2 | $42 |
| Ironwood Pharmaceuticals, Inc | 2 | $38 |
| Boston Scientific | 2 | $37 |
| Nestle Healthcare Nutrition Inc. | 2 | $35 |
| Sanofi | 2 | $35 |
| Vivus LLC | 2 | $30 |
| Merck | 2 | $27 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| Intercept Pharmaceuticals, Inc. | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $12 |
| Endogastric Solutions, Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLENPIQ$1,569
How this compares
$332,188 in reported general payments places this provider in the 90th percentile of 336 gastroenterology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 13 | $343,843 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $67,509 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 341 | $20,589 |
| Mesalamine | 15 | $7,081 |
| Balsalazide Disodium | 12 | $4,893 |
| Pantoprazole Sodium | 147 | $2,805 |
| Budesonide DrBudesonide | 15 | $2,622 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 13 | $2,057 |
| Famotidine | 81 | $1,514 |
| Esomeprazole Magnesium | 28 | $1,378 |
| Omeprazole | 108 | $1,351 |
| Lansoprazole | 21 | $718 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 23 | $342 |
| Dicyclomine Hcl | 24 | $341 |
| Amitriptyline Hcl | 26 | $317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $94 | $343,84313 claims |
| UCB, Inc.Cimzia (2 Pack) | $141 | $67,50911 claims |
| Braintree Laboratories, Inc.Sutab | $34,231 | $2,05713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 336 gastroenterology providers in Tennessee.
Other gastroenterology in Ooltewah
- Ziad YounesGermantown$15.6M
- Robert HerringNashville$3.2M
- Dawn Borromeo BeaulieuNashville$2.1M
- David SchwartzNashville$1.4M
- Kevin FinneganHermitage$1.4M
- Baldeep PablaNashville$1.2M
- Sara HorstNashville$1.2M
- Chakradhar ReddyJohnson City$884K
- Michael PoraykoNashville$870K
- Saras SharmaNashville$870K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.